Masimo (NASDAQ:MASI) Rating Lowered to Market Perform at Raymond James Financial

Masimo (NASDAQ:MASI) was downgraded by equities researchers at Raymond James Financial from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Friday.

Several other research firms have also issued reports on MASI. Weiss Ratings reissued a “sell (d)” rating on shares of Masimo in a research report on Thursday, January 22nd. Wolfe Research lowered shares of Masimo from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 19th. Stifel Nicolaus set a $180.00 target price on shares of Masimo in a report on Tuesday, February 17th. Wells Fargo & Company upgraded Masimo to a “hold” rating in a research report on Wednesday, March 18th. Finally, BTIG Research cut Masimo from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 18th. Eight equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus price target of $181.17.

Masimo Price Performance

Shares of NASDAQ MASI opened at $176.89 on Friday. The company has a current ratio of 2.49, a quick ratio of 1.47 and a debt-to-equity ratio of 0.72. The stock has a fifty day simple moving average of $159.23 and a two-hundred day simple moving average of $148.12. Masimo has a 1-year low of $125.94 and a 1-year high of $179.00. The firm has a market cap of $9.50 billion, a price-to-earnings ratio of -16.78, a price-to-earnings-growth ratio of 1.80 and a beta of 1.21.

Institutional Trading of Masimo

Hedge funds and other institutional investors have recently bought and sold shares of the company. Corient Private Wealth LLC boosted its holdings in Masimo by 1.2% in the 4th quarter. Corient Private Wealth LLC now owns 340,230 shares of the medical equipment provider’s stock valued at $44,250,000 after purchasing an additional 4,015 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in shares of Masimo in the fourth quarter worth $116,000. Pacer Advisors Inc. increased its holdings in shares of Masimo by 21.1% in the fourth quarter. Pacer Advisors Inc. now owns 7,360 shares of the medical equipment provider’s stock worth $957,000 after purchasing an additional 1,280 shares during the period. Virtu Financial LLC purchased a new stake in shares of Masimo in the fourth quarter worth $258,000. Finally, T. Rowe Price Investment Management Inc. raised its position in shares of Masimo by 9.6% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,330,158 shares of the medical equipment provider’s stock worth $303,061,000 after buying an additional 203,395 shares in the last quarter. Institutional investors own 85.96% of the company’s stock.

Masimo Company Profile

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.